Users Online: 746
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Reader Login
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Citation statistics : Table of Contents
   2012| October-December  | Volume 1 | Issue 2  
    Online since November 22, 2012

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
The role of honey in healing of bedsores in cancer patients
Aramita Saha, Subrata Chattopadhyay, Md. Azam , Prabir Kr Sur
October-December 2012, 1(2):66-71
DOI:10.4103/2278-330X.103714  PMID:24455516
Bacground: Honey was used to treat infected wounds as long as 2000 years before bacteria were discovered. It has been reported to have inhibitory action to around 50 species of bacteria and fungi (aspergillus, penicillium). Usually, Metronidazole powder is used in our palliative clinic for wound healing due to low cost & effectivity. Honey is cheap, easily available ingredient with high astringent activity. Objective: Objectives of the study were to find out the effectiveness of Honey in terms of rate of wound healing & pain control in bedsores of cancer patients. Materials and Methods: 40 cancer patients with bedsore wounds were randomly assigned (1:1 ratio i.e. 20 in each arm) for Study Arm (Honey plus Metronidazole powder) and Control Arm (only Metronidazole powder), attending Palliative clinic of our department in between July 2010 to September 2011.Washing of the wound with normal saline done daily before application of above medicaments. Change of posture & soft bed were encouraged in both groups. A pre designed interview proforma, standardised Bates Jensen Wound Assessment Tool and Visual Analogue Pain assessment scale were used to collect and assess data. Results: There was significant difference in wound healing status (F value = 6.523; Critical Difference =14.03, P<0.05) from day 10 and pain reduction also (F value = 6.638 and Critical Difference = 1.667, P<0.05) from day 7 in study arm. Conclusion: Application of honey dressing provides a better wound healing, rapid pain relief in cancer patients with bedsores in palliative settings.
  8 9,208 1,372
Post-chemotherapy arthralgia and arthritis in lung cancer
Aref H Amiri, Soleiman Jaferian
October-December 2012, 1(2):72-75
DOI:10.4103/2278-330X.103715  PMID:24455517
Objective: Evaluate the characteristics of arthritis, arthralgia and musculoskeletal pain after chemotherapy in patients with lung cancer. Materials and Methods: In this study, we evaluate the characteristics of 17 patients with joint symptoms following receiving chemotherapy for lung cancer. Demographic information of patients including sex, age, time of rheumatologic findings after starting of chemotherapy, time of improvement after starting of medication, and relevant laboratory findings for each patient. Results: A total of seventeen patients (six women with mean age 41.2 ± 5.2 years and 11 men with mean age 42.5 ± 8.2) that received standard chemotherapy for lung cancer according to stage of disease. Joint symptoms usually began about seven months after the first session of chemotherapy. Patients had an average of two tender joints and 1 hr of morning stiffness. Four patients were positive for anti-nuclear antibody, and none of patient was positive for rheumatoid factor. Non-steroidal anti-inflammatory drugs, disease modifying anti-rheumatic drugs (DMARD), corticosteroids, and venlafaxine were prescribed. Four patients did not show an improvement. Follow-up was available for all patients. 11 patients showed favorable responses, characterized by a significant decrease (more than 50%) in morning stiffness, pain, and tender joint counts after a mean of three months' treatment. Two patients had complete resolution of symptoms and did not required further medications for arthritis, arthralgia or musculoskeletal pain. Conclusion: Chemotherapy-related arthropathy in lung cancer is not uncommon. Early treatment with NSAID, DMARD, and corticosteroids is effective in the majority of patients.
  6 2,337 345
Fluoride levels and osteosarcoma
Simmi Kharb, Ravindra Sandhu, Zile Singh Kundu
October-December 2012, 1(2):76-77
DOI:10.4103/2278-330X.103717  PMID:24455518
Context: Osteosarcoma is a rare malignant bone tumor, commonly occurring in the age group of 10 to 24 years. Recent reports have indicated that there is a link between fluoride exposure and osteosarcoma. Aims: The present study was planned to analyze serum levels of fluoride in patients of osteosarcoma and fluoride content of their drinking water. Settings and Design: The present study was carried out comparing 10 patients of osteosarcoma and 10 healthy volunteers (who served as controls). Materials and Methods: Serum and drinking water fluoride levels were estimated by ion selective electrode. Statistical analysis used: The data were computed as mean ± SD and Student's t test was applied. Results: Both, the serum and drinking water fluoride levels, were significant by higher in patients with osteosarcoma as compared to controls (P < 0.05, P < 0.001, respectively). Conclusions: These results suggest a link between fluoride exposure and osteosarcoma.
  5 2,491 419
Role of bacteria in oral carcinogenesis
R Rajeev, Kanaram Choudhary, Swagatika Panda, Neha Gandhi
October-December 2012, 1(2):78-83
DOI:10.4103/2278-330X.103719  PMID:24455519
Oral cancer is the most common cancer diagnosed in Indian men and is the leading cause of cancer deaths. It is considered as a multistep and multifactorial disease. Besides accumulation of genetic mutations, numerous other carcinogens are involved. In this category, viral and chemical carcinogens are well studied and documented. However, in the oral cavity, the role of microbiota in carcinogenesis is not known. Microbial populations on mouth mucosa differ between healthy and malignant sites, and certain oral bacterial species have been linked with malignancies, but the evidence is still weak in this respect. Nevertheless, oral microorganisms inevitably up-regulate cytokines and other inflammatory mediators that affect the complex metabolic pathways, and may thus be involved in carcinogenesis. Poor oral health associates statistically with prevalence of many types of cancer such as pancreatic and gastrointestinal cancer. This review presents possible carcinogenesis pathway involved in bacterial carcinogenesis, commonly implicated bacteria in oral carcinogenesis, and their role in cancer therapeutics as well.
  5 3,218 738
Emergency percutaneous tracheostomy in two cancer patients with difficult airway: An alternative to cricothyroidotomy?
Prashant Nasa, Akhilesh Singh, Deven Juneja, Nitin Garg, Omender Singh, Yash Javeri
October-December 2012, 1(2):90-92
DOI:10.4103/2278-330X.103722  PMID:24455521
Inability to intubate and/or ventilate either due to distorted neck anatomy or restricted mouth opening is uncommon but potentially hazardous clinical scenario in head and neck cancer patients. Emergency cricothyroidotomy in such patients may provide a means of oxygenating the patient, but in practice has limitations and does not establish a definitive airway. We report 2 cases who had distorted face and neck anatomy in which percutaneous tracheostomy was done as an emergency life-saving procedure when other measures to obtain a definitive airway failed.
  2 2,542 274
Gorham disease of mandible treated with post-operative radiotherapy
Rakesh Kumar Gupta, Milind Kumar, Arun Verma, Subhash Pandit, Karuna Singh, Shipra Agarwal, Bidhu K Mohanti, Goura Kishore Rath
October-December 2012, 1(2):95-97
DOI:10.4103/2278-330X.103726  PMID:24455523
  2 2,848 288
The scenario of presentation of young females in a rural cancer hospital of North India: An initial experience
Vivek Tiwari, Piyush Shukla, Gourav Gupta
October-December 2012, 1(2):63-65
DOI:10.4103/2278-330X.103712  PMID:24455515
A total of 51 cases of young females aged between 18-35 years were prospectively studied for the presentation in a Rural Charitable Cancer hospital in north India during the period August 2011 to April 2012. Breast related symptoms comprised 27 (52.94%) cases, out of which 10 (19.60%) were proven malignant. Other cases seen were Gynecological (Gyn) 8 (15.68%), Head and Neck (H and N) 5 (9.80%), Gastrointestinal (GI) 4 (7.84%), Lymphomas 3 (5.88%) and 2 (3.92%) cases each of Bone Tumors and Central Nervous System (CNS) tumors. Breast related symptoms constituted the major presentation in young females (aged 18-35 years) in our Rural Cancer Hospital. This high percentage of Breast related symptoms points towards the increasing trend of Breast malignancies possibly overtaking cancer cervix in rural India, as already in the urban settlements of India as well as the increasing awareness in the females of rural India regarding early symptoms of carcinoma Breast.
  2 1,847 261
Composite pheochromocytoma
Rakesh Rai, Suhitha Gajanthody, Jnaneshwari Jayaram, Rajeev Kumar Chaudhry
October-December 2012, 1(2):98-99
DOI:10.4103/2278-330X.103727  PMID:24455524
  1 1,479 254
Using p53 to help diagnose ovarian cancer
Shweta Bansal
October-December 2012, 1(2):56-57
DOI:10.4103/2278-330X.103708  PMID:24455512
  1 1,357 309
A cytohistological study of p53 overexpression in ovarian neoplasms
Monisha Choudhury, Seema Goyal, Mukta Pujani, Meenu Pujani
October-December 2012, 1(2):59-62
Background: The present study was undertaken to evaluate the diagnostic accuracy of imprint cytology in ovarian neoplasms, investigate the biological significance of p53 expression in malignant ovarian tumors and correlate it with histological type, grade and stage of tumor. Material and Methods: A total of 50 cases including 25 prospective and 25 retrospective cases were studied. Imprint cytology was performed on 25 ovarian tumors and compared with histopathological diagnosis. p53 immunohistochemistry was performed on all 50 cases. Results: On immunohistochemistry, all the benign tumors were negative for p53 while 42% of primary ovarian malignant tumors were positive. p53 expression was found to have a diagnostic value in differentiating benign from malignant tumors. p53 overexpression did not show any significant correlation with prognostic factors as stage of disease, grade of differentiation and type of tumor. Conclusion: The present study confirms the importance of p53 tumor suppressor gene expression as documented by immunohistochemistry in the differentiation of malignant and benign ovarian tumors.
  1 1,673 322
Overview of recent developments in chronic lymphocytic leukemia
Preetesh Jain, Kanti R Rai
October-December 2012, 1(2):84-89
DOI:10.4103/2278-330X.103721  PMID:24455520
Multiple advances have been made in our understanding of pathobiology of chronic lymphocytic leukemia (CLL). These developments in the laboratory include new prognostic markers, risk stratification of the disease and newer therapeutic agents in CLL. These advances in CLL have come a long way in the past three decades since the development of Rai and Binet clinical staging systems. Important strides in the pathobiology, from defining mutational status of IGHV, to B-cell receptor (BCR) signaling pathways and CLL microenvironment have made a major difference in our understanding of this disease. Mutational status of immunoglobulin heavy chain genes (IGHV), CD38 and Zap-70, chromosomal aberrations and newer mutations, are the most clinically relevant prognostic markers. Chemoimmunotherapy (CIT) has become the treatment of choice for young and fit CLL patients. Various inhibitors of BCR signaling pathways and immunomodulatory drugs have shown efficacy in clinical trials. The most recent advance is the use of chimeric antigen receptor therapy (CAR) based on autologous T-lymphocytes. Nevertheless, CLL remains an incurable disease today. Coordinated developments between laboratory and clinic will hopefully translate into a cure for CLL. This short review focuses on advances in prognostication and therapy in CLL.
  1 4,160 736
Osteoclastic giant cell rich metaplastic carcinoma in malignant phylloides: A rare entity
Yasmin A Momin, Bhavana M Bharambe, Sameer A.H Ansari, Bharat A Ghodke
October-December 2012, 1(2):93-95
DOI:10.4103/2278-330X.103724  PMID:24455522
  - 1,289 195
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Amol Dongre, Kumar Prabhash, Vanita Noronha
October-December 2012, 1(2):53-55
DOI:10.4103/2278-330X.103707  PMID:24455511
  - 1,762 289
The changing landscape of cancer in rural setting
Shweta Bansal, Vanita Noronha
October-December 2012, 1(2):58-58
DOI:10.4103/2278-330X.103709  PMID:24455513
  - 1,253 221